Blood neurofilament light levels segregate treatment effects in multiple sclerosis.

Bénédicte DelcoigneAli ManouchehriniaChristian BarroPascal BenkertZuzanna MichalakLudwig KapposDavid LeppertJon A TsaiTatiana PlavinaBernd C KieseierJan LyckeLars AlfredssonIngrid KockumJens KuhleTomas OlssonFredrik Piehl

Published in: Neurology (2020)

Choice of DMT in RRMS is significantly associated with degree of reduction in pNfL, which supports a role for pNfL as a drug response marker.

Keyphrases

multiple sclerosis
emergency department
combination therapy
decision making
adverse drug